CD274 and cervical cancer: The SKYSCRAPER‐04 study compared atezolizumab (anti‐PD‐L1) with and without tiragolumab (anti‐TIGIT [T‐cell immunoreceptor with Ig and ITIM domains]), in patients with metastatic or recurrent PD‐L1 positive cervical cancer.35